For sales

📢 Highlights from April 07 to 11 in the world of pharma and healthcare! 🗞️👀

AbbVie ( EC, Approval ) European Commission Approves AbbVie's RINVOQ® (upadacitinib) for Treatment of Giant Cell Arteritis in Adults Johnson & Johnson ( Clinica data, Phase 3) Johnson & Johnson highlights 18-Month data from its Phase 3 Vivacity-MG3, demonstrating nipocalimab’s sustained reduction in IgG antibodies and continued improvement in gMG symptoms Johnson & Johnson + Halozyme Therapeutics ( EC, Approval) European Commission grants approval for Johnson & Johnson's SC RYBREVANT® with ENHANZE® in patients with advanced EGFR-mutated non-small cell lung cancer Remegen ( Clinica data, Phase 3) Remegen reports positive topline Phase 3 data for telitacicept in gMG: 98.1% achieve clinically meaningful MG-ADL improvement; 87% show QMG score reduction at week 24 Avidity Biosciences ( Ophan Drug Designation ) Avidity Biosciences secures Orphan Drug Designation in Japan for delpacibart etedesiran, supporting ongoing development in myotonic dystrophy type 1
Download

Connect with us

Please fill in the information below, and we'll get back to you.